{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mulders MCF"],"funding":["Neuroendocrine Tumor Research Foundation","KWF Kankerbestrijding"],"pagination":["e70000"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11544441"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(6)"],"pubmed_abstract":["Currently, the available literature provides insufficient support to differentiate between primary ovarian neuroendocrine tumors (PON) and neuroendocrine ovarian metastases (NOM) in patients. For this reason, patients with a well-differentiated ovarian neuroendocrine tumor (NET) were identified through electronic patient records and a nationwide search between 1991 and 2023. Clinical characteristics were collected from electronic patient files. This resulted in the inclusion of 71 patients with NOM and 17 patients with PON. Histologic material was stained for Ki67, SSTR2a, CDX2, PAX8, TTF1, SATB2, ISLET1, OTP, PDX1, and ARX. DNA methylation analysis was performed on a subset of cases. All PON were unilateral and nine were found within a teratoma (PON-T+). A total of 78% of NOM were bilater"],"journal":["The journal of pathology. Clinical research"],"pubmed_title":["Clinicopathological and epigenetic differences between primary neuroendocrine tumors and neuroendocrine metastases in the ovary."],"pmcid":["PMC11544441"],"funding_grant_id":["12978","654863"],"pubmed_authors":["Roes EM","Geisenberger C","van Velthuysen MF","de Herder WW","Mulders MCF","Hofland J","Verschuur AVD","Brosens LA","de Lussanet de la Sabloniere QG"],"additional_accession":[]},"is_claimable":false,"name":"Clinicopathological and epigenetic differences between primary neuroendocrine tumors and neuroendocrine metastases in the ovary.","description":"Currently, the available literature provides insufficient support to differentiate between primary ovarian neuroendocrine tumors (PON) and neuroendocrine ovarian metastases (NOM) in patients. For this reason, patients with a well-differentiated ovarian neuroendocrine tumor (NET) were identified through electronic patient records and a nationwide search between 1991 and 2023. Clinical characteristics were collected from electronic patient files. This resulted in the inclusion of 71 patients with NOM and 17 patients with PON. Histologic material was stained for Ki67, SSTR2a, CDX2, PAX8, TTF1, SATB2, ISLET1, OTP, PDX1, and ARX. DNA methylation analysis was performed on a subset of cases. All PON were unilateral and nine were found within a teratoma (PON-T+). A total of 78% of NOM were bilater","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-07-16T21:45:54.78Z","creation":"2025-04-06T01:44:43.531Z"},"accession":"S-EPMC11544441","cross_references":{"pubmed":["39513463"],"doi":["10.1002/2056-4538.70000"]}}